Item 2. Properties
ITEM 2.
Properties
As
of December 31, 2025, we lease a 14,507 square foot manufacturing facility in Irvine, California under a lease that expires on September
30, 2027. Our facility is designed expressly for the manufacture of biologic vascular grafts and is equipped for research and development,
prototype fabrication, cGMP manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices. We believe
that our facilities are sufficient for the near future as there is present capacity to manufacture up to approximately 20,000 venous
valves per year to meet potential market demands.
ITEM 3.
Legal Proceedings
None.
ITEM 4.
Mine and Safety Disclosures
Not
applicable.
PART
II
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.